Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C

Abstract

Interferons are able to exert an antiviral effect against hepatitis C virus (HCV) infection via induction of interferon-stimulated genes (ISGs). This study tested whether differential expression of an important ISG with antiviral properties, tripartite motif 22 (TRIM22), correlates with a response to Peg-IFNα-2a/RBV combination therapy in treatment-naive patients with chronic hepatitis C. A total of 32 patients with chronic hepatitis C were enrolled in this study and received standard Peg-IFNα-2a/RBV combination therapy. HCV viral load was measured during treatment, at the end of treatment, and 6 months later to determine the treatment outcome. Quantitative real-time PCR was used to assess the expression levels of TRIM22 in peripheral blood mononuclear cells (PBMCs) of the patients before antiviral therapy. Of the 32 patients, 26 (81.3%) were males. In this study, there were 16 (50%) individuals with a sustained virologic response (SVR), and a virologic relapse was observed in the remaining half of the subjects. Testing for the presence of genomic HCV RNA in blood during therapy revealed a rapid virologic response (RVR) in 10 (31.2%) and a partial and complete early virologic response (EVR) in 8 (25%) and 24 (75%) of the cases, respectively. TRIM22 mRNA levels were significantly higher in patients with a sustained virologic response than in relapsers (P = 0.002) and in patients with a rapid virologic response than in the others (P = 0.040). No statistically significant difference was seen in the expression of TRIM22 between patients with a partial early virologic response and a complete early virologic response. This study showed that pretreatment upregulation of TRIM22 may be associated with responsiveness to Peg-IFNα-2a/RBV combination therapy.

Detection of HCV genome in peripheral blood mononuclear cells of Iranian seropositive and HCV RNA negative in plasma of patients with beta‐thalassemia major: Occult HCV infection

“…Viral RNA from plasma and PBMC (approximately 3‐5 × 10 6 cells) samples were extracted using High Pure Viral Nucleic Acid Kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s procedure. Purity and concentration of viral RNA were determined using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Wilmington, MA) . For synthesis of complementary DNA (cDNA), 0.5 µg of RNA template was used with a reaction mixture of 2 µL of 100 pmol random hexamer, 4 µL of the 5× reverse transcriptase (RT) buffer, 2 µL of the mix deoxynucleotide triphosphate (10 mM), 200 units of Moloney murine leukemia virus RT (Fermentas GmbH, St. Leon‐Rot, Germany), 8 units of the RNase inhibitor (Fermentas GmbH), as well as 1.4 µL of diethyl‐pyrocarbonate treated water.…”

“…For synthesis of complementary DNA (cDNA), 0.5 µg of RNA template was used with a reaction mixture of 2 µL of 100 pmol random hexamer, 4 µL of the 5× reverse transcriptase (RT) buffer, 2 µL of the mix deoxynucleotide triphosphate (10 mM), 200 units of Moloney murine leukemia virus RT (Fermentas GmbH, St. Leon‐Rot, Germany), 8 units of the RNase inhibitor (Fermentas GmbH), as well as 1.4 µL of diethyl‐pyrocarbonate treated water. This mixture was incubated at 42°C for 30 minutes (for RT reaction), and then at 70°C for 10 minutes to stop RT activity in a thermocycler …”

Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients

“…Furthermore, TRIM5 is an E3 ubiquitin ligase that promotes activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activator protein 1 (AP-1), which play an important role in innate immune response [20, 21]. TRIM22 protein, as well as TRIM5, is an ISG upregulated upon IFN administration to HCV-infected patients and it is also able to induce innate signaling pathways [15, 22]. TRIM22 is a natural antiviral effector of HIV-1 [23].…”

The Presence of Autoantibodies to Cytoplasmic Rod and Ring Particles in the Serum of Patients with Chronic Hepatitis C Virus Infection

“…The samples were stored at -80°C. The exclusion criteria included coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) (25). The current study was approved by the Ethics Committee of Iran University of Medical Sciences (IUMS), Tehran, Iran.…”